红日药业：股东姚小青及高管拟合计减持不超1.576%股份

Core Viewpoint - The major shareholder and executives of Hongri Pharmaceutical plan to reduce their holdings, indicating potential changes in ownership structure and possible implications for the company's stock performance [1] Shareholder Reduction - Shareholder Yao Xiaoqing, holding over 5% of shares, intends to reduce holdings by up to 46,936,300 shares, which represents approximately 1.5624% of the total share capital [1] - Executive Chen Ruiqiang plans to reduce holdings by up to 169,000 shares, accounting for about 0.0056% of the total share capital [1] - Executive Zhang Kun aims to reduce holdings by up to 232,000 shares, which is around 0.0077% of the total share capital [1] Reasons and Methods - The reason for the reduction in holdings is stated as personal funding needs [1] - The reduction will be executed through centralized bidding or block trading [1] - The reduction period is set for three months starting fifteen trading days after the announcement [1]